Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Toge

Showing results (51-60 of 243) with videos related to

Pageof 25
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 2, 2001
[A case of inoperable advanced gall bladder cancer responding to intra-arterial infusion of 5-fluorouracil (5-FU) and leucovorin (LV)]K Ohta, A Sawamura, E Miyahara, et al.
The Japanese Journal of Surgery|September 1, 1991
Clinical significance of P-glycoprotein expression analyzed by immunohistochemical staining in cancer tissuesR Kim, N Hirabayashi, M Nishiyama, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 1, 1993
[Mitomycin C and its bioreduction: relevance of NAD(P)H: quinone oxidoreductase activity to mitomycin C-induced DNA damage and cytotoxicity]M Nishiyama, S Saeki, K Aogi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1985
[Clinical experience in LC-9018 Lactobacillus preparation]T Toge, K Araya, H Yamada, et al.
Oncology Reports|April 11, 2001
A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor actionR Kim, A Osaki, K Tanabe, et al.
International Journal of Oncology|May 10, 2011
Biochemical modulation of Doxorubicin using an isoprenoid derivative, N-1379 - plasma transmembrane potential as a target siteK Aogi, M Nishiyama, S Saeki, et al.
In Vivo (Athens, Greece)|May 1, 1994
Defective natural killer activity in gastric cancer patients: possible involvement of suppressor factor receptorY Yamaguchi, I Takashima, M Funakoshi, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1991
The augmentative effect of a protein-bound polysaccharide (PSK) on tumoricidal activity of the soluble factor produced by a streptococcal preparation (OK-432)-activated macrophagesN Baba, H Kawami, Y Sato, et al.
Cancer|July 1, 1991
Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancerH Mukaida, M Toi, T Hirai, et al.
The Japanese Journal of Surgery|December 1, 1976
Lymphocyte responsiveness to phytohemagglutinin (PHA) and serum inhibitory effect in patients with gastric cancerT Toge, H Ikeda, N Senoo, et al.
Pageof 25

Showing results (51-60 of 243) with videos related to

Sort By:
Pageof 25
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 2, 2001
[A case of inoperable advanced gall bladder cancer responding to intra-arterial infusion of 5-fluorouracil (5-FU) and leucovorin (LV)]K Ohta, A Sawamura, E Miyahara, et al.
The Japanese Journal of Surgery|September 1, 1991
Clinical significance of P-glycoprotein expression analyzed by immunohistochemical staining in cancer tissuesR Kim, N Hirabayashi, M Nishiyama, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 1, 1993
[Mitomycin C and its bioreduction: relevance of NAD(P)H: quinone oxidoreductase activity to mitomycin C-induced DNA damage and cytotoxicity]M Nishiyama, S Saeki, K Aogi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1985
[Clinical experience in LC-9018 Lactobacillus preparation]T Toge, K Araya, H Yamada, et al.
Oncology Reports|April 11, 2001
A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor actionR Kim, A Osaki, K Tanabe, et al.
International Journal of Oncology|May 10, 2011
Biochemical modulation of Doxorubicin using an isoprenoid derivative, N-1379 - plasma transmembrane potential as a target siteK Aogi, M Nishiyama, S Saeki, et al.
In Vivo (Athens, Greece)|May 1, 1994
Defective natural killer activity in gastric cancer patients: possible involvement of suppressor factor receptorY Yamaguchi, I Takashima, M Funakoshi, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1991
The augmentative effect of a protein-bound polysaccharide (PSK) on tumoricidal activity of the soluble factor produced by a streptococcal preparation (OK-432)-activated macrophagesN Baba, H Kawami, Y Sato, et al.
Cancer|July 1, 1991
Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancerH Mukaida, M Toi, T Hirai, et al.
The Japanese Journal of Surgery|December 1, 1976
Lymphocyte responsiveness to phytohemagglutinin (PHA) and serum inhibitory effect in patients with gastric cancerT Toge, H Ikeda, N Senoo, et al.
Pageof 25